KP TISSUE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.28 CAD | -0.24% |
|
-0.24% | -8.20% |
| Mar. 08 | National Bank Reviews KP Tissue's Q4 Results | MT |
| Mar. 07 | KP Tissue Swings to Profit in Q4; Declares Dividend; Kruger Products' Q4 Profit, Revenue Climbs | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 92.89 | 105 | 103 | 100.9 | 89.87 | 82.54 | - | - |
| Enterprise Value (EV) 1 | 578.9 | 729.8 | 103 | 100.9 | 89.87 | 1,182 | 1,212 | 82.54 |
| P/E ratio | 286 x | 25.5 x | - | - | -16.9 x | - | - | - |
| Yield | 7.46% | 6.69% | 6.92% | 7.1% | - | 8.7% | 8.7% | - |
| Capitalization / Revenue | 0.06 x | 0.07 x | 0.07 x | 0.06 x | 0.05 x | 0.04 x | 0.04 x | - |
| EV / Revenue | 0.4 x | 0.48 x | 0.07 x | 0.06 x | 0.05 x | 0.6 x | 0.6 x | - |
| EV / EBITDA | 3.99 x | 3.69 x | 0.67 x | 0.87 x | 0.38 x | 5.04 x | 5.05 x | 0.32 x |
| EV / FCF | -14 x | -17.6 x | - | -1.31 x | - | -19.1 x | 19.7 x | - |
| FCF Yield | -7.15% | -5.67% | - | -76.3% | - | -5.25% | 5.07% | - |
| Price to Book | 1.2 x | 1.58 x | 1.36 x | 1.36 x | - | 0.99 x | 0.95 x | - |
| Nbr of stocks (in thousands) | 9,626 | 9,752 | 9,895 | 9,946 | 9,964 | 9,968 | - | - |
| Reference price 2 | 9.650 | 10.77 | 10.41 | 10.14 | 9.020 | 8.280 | 8.280 | 8.280 |
| Announcement Date | 3/12/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,434 | 1,516 | 1,465 | 1,681 | 1,873 | 1,967 | 2,032 | - |
| EBITDA 1 | 145 | 197.8 | 153.4 | 116 | 238.6 | 234.2 | 239.8 | 262 |
| EBIT | 75.61 | 129 | 67.71 | 13.12 | 137.2 | - | - | - |
| Operating Margin | 5.27% | 8.51% | 4.62% | 0.78% | 7.33% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | 2.098 | 27.31 | - | - | -5.313 | - | - | - |
| Net margin | 0.15% | 1.8% | - | - | -0.28% | - | - | - |
| EPS | 0.0337 | 0.4226 | - | - | -0.5336 | - | - | - |
| Free Cash Flow 1 | -41.4 | -41.4 | - | -76.9 | - | -62 | 61.45 | - |
| FCF margin | -2.89% | -2.73% | - | -4.57% | - | -3.15% | 3.02% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 25.62% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.7200 | 0.7200 | 0.7200 | 0.7200 | - | 0.7200 | 0.7200 | - |
| Announcement Date | 3/12/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 391.4 | 424 | 398.7 | 397.5 | 427 | 458.1 | 451 | 466.3 | 473.4 | 482.3 | 474.4 | 490.3 | 498.4 | 503.7 |
| EBITDA 1 | 40.31 | 38.34 | 29.06 | 11.82 | 30.71 | 44.41 | 49.96 | 55.05 | 72.38 | 61.22 | 60.28 | 60.33 | 61.17 | 58.43 |
| EBIT | 16.85 | 16.45 | 6.029 | - | 5.918 | 11.26 | 25.7 | 31.06 | 47.04 | 33.42 | - | - | - | - |
| Operating Margin | 4.3% | 3.88% | 1.51% | - | 1.39% | 2.46% | 5.7% | 6.66% | 9.94% | 6.93% | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | 0.1800 | - | 0.1800 | 0.1800 | 0.1800 | 0.1800 |
| Announcement Date | 11/12/21 | 3/10/22 | 5/12/22 | 8/11/22 | 11/9/22 | 3/9/23 | 5/11/23 | 8/10/23 | 11/8/23 | 3/7/24 | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 486 | 625 | - | - | - | 1,099 | 1,129 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.351 x | 3.158 x | - | - | - | 4.692 x | 4.707 x | - |
| Free Cash Flow 1 | -41.4 | -41.4 | - | -76.9 | - | -62 | 61.5 | - |
| ROE (net income / shareholders' equity) | - | - | 1.74% | -13.7% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 8.010 | 6.800 | 7.670 | 7.440 | - | 8.340 | 8.710 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 175 | 295 | - | 116 | - | 211 | 60 | - |
| Capex / Sales | 12.2% | 19.45% | - | 6.88% | - | 10.73% | 2.95% | - |
| Announcement Date | 3/12/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
8.28
CAD
Average target price
9.5
CAD
Spread / Average Target
+14.73%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.20% | 60.29M | |
| +11.30% | 45.54B | |
| -9.06% | 17.38B | |
| -9.81% | 3.89B | |
| +3.08% | 3.6B | |
| -13.60% | 1.56B | |
| +40.30% | 1.26B | |
| +13.83% | 928M | |
| +24.39% | 820M | |
| +25.47% | 436M |
- Stock Market
- Equities
- KPT Stock
- Financials KP Tissue Inc.
